Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bausch + Lomb has acquired assets and US rights of Zirgan (ganciclovir ophthalmic gel 0.15%) from Sirion Therapeutics.
Subscribe to our email newsletter
Zirgan was approved by the FDA as a topical anti-viral for the treatment of acute herpetic keratitis (corneal ulcers). In 2007, Sirion Therapeutics acquired a license for the Zirgan product technology and trademark from Laboratoires Thea, headquartered in France, for the US market.
Zirgan is available by prescription through US pharmacies, with more expected to carry the product in the coming months following its acquisition by Bausch + Lomb.
Brent Saunders, CEO of Bausch + Lomb, said: “We’re intensely focused on understanding and serving the needs of our customers and their patients. Our acquisition of Zirgan is an important step in further expanding our innovative product portfolio, which spans the ophthalmic spectrum.”
Philip Gioia, head of North America Pharmaceuticals at Bausch + Lomb, said: “Our acquisition of Zirgan reflects our strategy to bring innovative products to the ophthalmic community. With its tolerability, convenience, and targeted anti-viral effect, we believe Zirgan will experience rapid adoption by U.S. physicians for the benefit of their patients.”